New drug plus chemotherapy for advanced stomach cancer with liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug (Retlirafusp alfa) combined with chemotherapy against a standard immunotherapy drug with chemotherapy for people with advanced stomach cancer that has spread to the liver. It aims to see if the new combination works better as a first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced stomach or lower esophagus cancer that has spread to your liver.
- You must not have had any prior treatment for advanced cancer (except if you finished adjuvant/neoadjuvant therapy more than 6 months before recurrence).
- You must be in good physical condition (able to take care of yourself and be up and about).
- You must not have serious autoimmune diseases or have received certain immunotherapies before.
- You must agree to use effective birth control during the study and for 120 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
This trial tests a combination of four treatments (two investigational drugs, a targeted therapy, and chemotherapy) as a first-line option for people with advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new combination of three drugs for stomach cancer that has progressed after initial immunotherapy. It aims to see if this combo can shrink tumors or slow cancer growth, potentially offering a new option for patients like you.
This trial tests a new drug combined with chemotherapy before surgery for stomach cancer that has spread to nearby areas. It aims to shrink the tumor to make surgery more successful.
This trial tests a new combination of drugs (Retlirafusp Alfa, Bevacizumab, and chemotherapy) with or without a short course of radiation for people with colorectal cancer that has spread only to the liver and who have not had any prior treatment. The goal is to see if this approach is safe and effective.
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
Hear when a new Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.